Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.
Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang J, Xiao N, Greil R, Rinnerthaler G, Gampenrieder SP, Heimberger AB, Berry DA, Barker A, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Magee D, Miglarese MR, Famulok M, Mayer G, Spetzler D.
Domenyuk V, et al. Among authors: voss a.
Nat Commun. 2018 Mar 23;9(1):1219. doi: 10.1038/s41467-018-03631-z.
Nat Commun. 2018.
PMID: 29572535
Free PMC article.